• DNA vaccine targeting BARF1 in vivo (286)• CRISPR-mediated deletion of PD-1 in LMP2A-specific   T cells targeting EBVaGC (251)• Combination of anti-PD-1 and adoptive NK cell   transfer targeting GC in vivo (291)• Efficacy of mesothelin-specific CAR-NK92 cells   demonstrated in xenograft models of GCs (292)• Combinatory targeting TIM-3/LAG-3/TIGIT as   alternative immune checkpoint in vitro (287)• Inhibition of F3-mediated platelet aggregation   reinvigorates NK cell activity in NPC and   EBVaGCs (298). This evidence concerns the gene TIGIT and nasopharyngeal carcinoma.